Adjust your brief
The preview updates as you change things. Nothing is kept until you save.
Preview · 8 items · about 10 min
- Erasca’s pan-RAS pill ERAS-0015 drew confirmed responses in 44% of 25 previously treated pancreatic cancer patients2 min
- The S&P 500 closes in correction as chip stocks fall about 10%2 min
- Why beef costs more this year1 min
- Revolution Medicines reported first-line data for daraxonrasib plus chemotherapy in metastatic pancreatic cancer1 min
- Anthropic closes its IPO at about $119.5 billion combined; the stock falls 8.98%1 min
- Who gets leave, and who does the care1 min
- Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint1 min
- Why there’s no tested way to can pumpkin butter at home1 min